

Vers 3.14		Revision Date: 30.09.2023		98 Number: 825-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014			
SEC	SECTION 1: Identification of the substance/mixture and of the company/undertaking							
1.1 F	1.1 Product identifier							
	Trade r	name	:	Timolol / Dorzolar	nide Formulation			
1.2 F	Relevan	t identified uses of t	he s	ubstance or mixt	ure and uses advised against			
Use of the Sub- stance/Mixture		the Sub-	:	Pharmaceutical				
	Recom on use	mended restrictions	:	Not applicable				
1.3 C	Details (of the supplier of the	saf	ety data sheet				
Company		ny	:	MSD 117 16th Road 1685 Halfway ho	use, Midrand, South Africa			
	Telepho	one	:	+27 11 655 3000				
		address of person sible for the SDS	:	EHSDATASTEW/	ARD@msd.com			
1.4 E	1.4 Emergency telephone number							

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated exposure, Category 1, Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

1

2

Hazard pictograms



Hazard statements

Signal word

H372 Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.



Version 3.14	Revision Date: 30.09.2023	SDS Number: 28825-00022		Date of last issue: 04.04.2023 Date of first issue: 06.11.2014
Precautionary statements		: P264 P270	Wash skin	thoroughly after handling. , drink or smoke when using this product.
		Respo	onse:	
		P314	Get medic	al advice/ attention if you feel unwell.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Dorzolamide	130693-82-2	Acute Tox. 4; H302 STOT RE 2; H373 (Central nervous system, Gastroin- testinal tract, Bone, Blood, Bladder)	>= 1 - < 10
(S)-3-[3-(tert-butylamino)-2- hydroxypropoxy]-4-morpholino-1,2,5- thiadiazole monomaleate	26921-17-5 248-111-5	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Lungs, Cardio- vascular system)	>= 0,1 - < 1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty



Version 3.14	Revision Date: 30.09.2023		9S Number: 825-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014	
			Get medical atten Wash clothing bet		
In cas	se of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.		
lf swa	llowed	:	If swallowed, DO Get medical atten Rinse mouth thore		
4.2 Most i	mportant symptoms a	nd e	effects, both acute	and delayed	
Risks		:		o organs through prolonged or repeated	
4.3 Indica	•	mec		I special treatment needed	
Treati	ment	:	i reat symptomati	cally and supportively.	
Suitab	uishing media ble extinguishing media itable extinguishing	:	Water spray Alcohol-resistant t Carbon dioxide (C Dry chemical None known.		
media					
5.2 Specia	al hazards arising from	the	e substance or mi	xture	
Speci fightin	fic hazards during fire- ng	:	Exposure to comb	oustion products may be a hazard to health.	
Hazaı ucts	rdous combustion prod-	:	Carbon oxides Nitrogen oxides (I Sulphur oxides Hydrogen chloride		
5.3 Advice	e for firefighters				
	al protective equipment efighters	:		e, wear self-contained breathing apparatus. ective equipment.	
Speci ods	fic extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do	



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.14	30.09.2023	28825-00022	Date of first issue: 06.11.2014

SECTION 6: Accidental release measures

6.1 Personal precautions, protec Personal precautions		e equipment and emergency procedures Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

F F C C C C C C C C C C C C C C C C C C	Soak up with inert absorbent material. For large spills, provide dyking or other appropriate contain- ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- bosal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
--	--

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.	
Local/Total ventilation Advice on safe handling	 Use only with adequate ventilation. Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and practice, based on the results of the workplace exposu sessment Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize releas environment. 	re as-
Hygiene measures	: If exposure to chemical is likely during typical use, prov	nue eye



Version 3.14	Revision Date: 30.09.2023	SDS Number: 28825-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014			
		place. Wher nated clothin The effective engineering appropriate industrial hy	tems and safety showers close to the working n using do not eat, drink or smoke. Wash contami- ng before re-use. e operation of a facility should include review of controls, proper personal protective equipment, degowning and decontamination procedures, giene monitoring, medical surveillance and the histrative controls.			
7.2 Condi	tions for safe storage	, including any in	compatibilities			
•	Requirements for storage areas and containers		Keep in properly labelled containers. Store in accordance with the particular national regulations.			
Advice on common storage		Strong oxidi	e substances and mixtures			
7.3 Specif	fic end use(s)					
-	Specific use(s)		: No data available			

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Dorzolamide	130693-82- 2	TWA	10 μg/m3 (OEB 3)	Internal
	Further inform	nation: Eye		
		Wipe limit	100 µg/100 cm²	Internal
(S)-3-[3-(tert- butylamino)-2- hydroxypropoxy]-4- morpholino-1,2,5- thiadiazole monomaleate	26921-17-5	TWA	10 μg/m3 (OEB 3)	Internal
	Further information: Eye, Skin			
		Wipe limit	100 µg/100 cm²	Internal

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.



Version 3.14	Revision Date: 30.09.2023		9S Number: 825-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014		
and t vices	Containment technologies suitable for controlling compounds are required to control at sour and to prevent migration of the compound to uncontrolled areas (e.g., open-face containme vices). Minimize open handling.					
Pers	onal protective equip	ment				
Eye/	ון n ע ק		Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.			
Hand	d protection					
М	Material		Chemical-resistar	nt gloves		
	Skin and body protection : W Ad be SU U		being performed suits) to avoid exp Use appropriate of	aboratory coat. arments should be used based upon the task (e.g., sleevelets, apron, gauntlets, disposable posed skin surfaces. degowning techniques to remove potentially		
	iratory protection	 contaminated clothing. If adequate local exhaust ventilation is not available of sure assessment demonstrates exposures outside the ommended guidelines, use respiratory protection. Particulates type (P) 		exhaust ventilation is not available or expo- demonstrates exposures outside the rec- lines, use respiratory protection.		
FI	пегтуре	:	Particulates type	(٢)		

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold		liquid colourless No data available No data available
рН	:	5,6
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available
range Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available

SAFETY DATA SHEET



Timolol / Dorzolamide Formulation

Version 3.14	Revision Date: 30.09.2023		Number: 25-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014
Rel De Sol Pai oct	ative vapour density ative density nsity ubility(ies) Water solubility tition coefficient: n- anol/water o-ignition temperature	: : :	No data available 1,02 No data available soluble No data available No data available	9
	composition temperature	:	No data available	9
	cosity Viscosity, kinematic plosive properties	-	No data available Not explosive	9
Oxi	dizing properties	:	The substance o	r mixture is not classified as oxidizing.
Fla Mo	er information mmability (liquids) lecular weight ticle size	:	No data available No data available No data available	9

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions					
Hazardous reactions	:	Can react with strong oxidizing agents.			

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.





ersion 14	Revision Date: 30.09.2023		OS Number: 825-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014
ECTION	I 11: Toxicological i	infor	mation	
.1 Infor	mation on toxicologic	al ef	fects	
Inforn expos	nation on likely routes o sure	of:	Inhalation Skin contact Ingestion Eye contact	
Acute	e toxicity			
Not c	assified based on avai	lable	information.	
Produ Acute	u <u>ct:</u> e oral toxicity	:	Acute toxicity e Method: Calcul	stimate: > 2.000 mg/kg ation method
<u>Com</u>	oonents:			
Dorzo	plamide:			
Acute	oral toxicity	:	LD50 (Rat): 1.9	027 mg/kg
			LD50 (Mouse):	1.320 mg/kg
Acute	inhalation toxicity	:	Remarks: No d	ata available
Acute	e dermal toxicity	:	Remarks: No d	ata available
• •	[3-(tert-butylamino)-2 oral toxicity	2-hyd :	roxypropoxy]-4 LD50 (Rat): 1.0	- morpholino-1,2,5-thiadiazole monomaleat 000 mg/kg
			LD50 (Mouse):	1.140 mg/kg
	toxicity (other routes on the stration)	of :	```	300 mg/kg ute: Intraperitoneal
			LD50 (Mouse): Application Ro	800 mg/kg ute: Subcutaneous
	corrosion/irritation lassified based on avai	lable	information.	
Com	oonents:			

• •		-		
Spe	cies		:	Rabbit
Meth	nod		:	Draize Test
Res	ult		:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Dorzolamide:



	Revision Date: 30.09.2023		S Number: 325-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014
Species	S	:	Monkey	
Result		:	Mild eye irritation	
(S)-3-[3	3-(tert-butylamino)	-2-hydr	oxypropoxy]-4-m	orpholino-1,2,5-thiadiazole monomaleat
Species	S	:	Rabbit	
Result		:	Mild eye irritation	
Species Result	S	:	Dog No eye irritation	
Respira	atory or skin sens	itisatio	n	
	ensitisation ssified based on ava	ailable i	information.	
Respira	atory sensitisation			
-	ssified based on av		nformation.	
<u>Compo</u>	onents:			
Dorzola	amide:			
Test Ty		:	Maximisation Tes	t
	ire routes	:	Skin contact	
Species Result	S	:	Guinea pig Weak sensitizer	
Germ c	cell mutagenicity			
Not clas	ssified based on ava	ailable i	nformation.	
<u>Compo</u>	onents:			
Dorzola	amide:			
Genoto	oxicity in vitro	:	Test Type: Chrom Result: negative	osomal aberration
			Test Type: Alkalin	e elution assay
			Test system: rat h	
			Result: negative	
				······································
			Test Type: In vitro	mammalian cell gene mutation test
			Test system: Chir	ese hamster fibroblasts
			Test system: Chir Result: negative	
Genoto	vxicity in vivo	:	Test system: Chir Result: negative Test Type: Bacter Result: negative Test Type: Cytoge	lese hamster fibroblasts ial reverse mutation assay (AMES)
Genoto	oxicity in vivo	:	Test system: Chir Result: negative Test Type: Bacter Result: negative	lese hamster fibroblasts ial reverse mutation assay (AMES)



sion 4	Revision Date: 30.09.2023	SDS Nu 28825-0		last issue: 04.04.2023 first issue: 06.11.2014
		Res	t: negative	
Geno	toxicity in vivo	Spe	Гуре: In vivo micronu es: Mouse	
			od: OECD Test Guide t: negative	line 474
Carci	nogenicity			
Not cl	assified based on ava	ailable inforr	ation.	
Comp	oonents:			
Dorzo	plamide:			
Speci		: Rat,	nale	
	cation Route	: Oral		
Expos	sure time	: 2 Ye		
			y/kg body weight	
Resul Rema		: nega		faction may not be relevant in by
Rema	IIKS	man		f action may not be relevant in hu
Speci	es	: Mou	е	
Applic	ation Route	: Oral		
	sure time		onth(s)	
Resul	t	: nega	IVe	
(S)-3-	[3-(tert-butylamino)-	2-hydroxyr	opoxy]-4-morpholin	o-1,2,5-thiadiazole monomalea
• •		2-hydroxy : Rat	opoxy]-4-morpholin	o-1,2,5-thiadiazole monomalea
Speci	es		opoxy]-4-morpholin	o-1,2,5-thiadiazole monomalea
Speci Applic		: Rat		o-1,2,5-thiadiazole monomalea
Speci Applic	es cation Route sure time	: Rat : Oral : 2 Ye		o-1,2,5-thiadiazole monomalea
Speci Applic Expos LOAE Resul	es cation Route sure time L t	: Rat : Oral : 2 Ye : 300 : nega	rs ng/kg body weight ive	o-1,2,5-thiadiazole monomalea
Speci Applic Expos LOAE Resul Targe	es cation Route sure time t t t Organs	: Rat : Oral : 2 Ye : 300 : nega : Adre	rs ng/kg body weight ive nal gland	
Speci Applic Expos LOAE Resul	es cation Route sure time t t t Organs	: Rat : Oral : 2 Ye : 300 : nega : Adre	rs ng/kg body weight ive nal gland	
Speci Applic Expos LOAE Resul Targe Rema	es cation Route sure time :L t t Organs urks es	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou	rs ng/kg body weight ive nal gland	
Speci Applic Expos LOAE Resul Targe Rema Speci Applic	es cation Route sure time :L t t Organs urks es cation Route	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral	rs ng/kg body weight ive al gland ignificance of these fi e, female	
Speci Applic Expose LOAE Resul Targe Rema Speci Applic Expose	es cation Route sure time L t t Organs trks es cation Route sure time	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 M	rs ng/kg body weight ive al gland ignificance of these fi e, female onths	
Speci Applic Expose LOAE Resul Targe Rema Speci Applic Expose LOAE	es cation Route sure time t t t Organs trks es cation Route sure time L	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 N : 500	rs ng/kg body weight ive al gland ignificance of these fi e, female onths ng/kg body weight	
Speci Applic Expos LOAE Resul Targe Rema Speci Applic Expos LOAE Resul	es cation Route sure time t t t Organs trks es cation Route sure time L t	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 N : 500 : nega	rs ng/kg body weight ive al gland ignificance of these fi e, female onths ng/kg body weight ive	ndings for humans is not certain.
Speci Applic Expos LOAE Resul Targe Rema Speci Applic Expos LOAE Resul	es cation Route sure time t t t Organs trks es cation Route sure time L t t t Organs	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 M : 500 : nega : Lung	rs ng/kg body weight ive al gland ignificance of these fi e, female onths ng/kg body weight ive s, Mammary gland, Ut	o-1,2,5-thiadiazole monomalea ndings for humans is not certain. terus (including cervix) ndings for humans is not certain.
Speci Applic Expose LOAE Resul Targe Rema Speci Applic Expose LOAE Resul Targe Resul Targe Rema	es cation Route sure time t t t Organs trks es cation Route sure time L t t t Organs	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 M : 500 : nega : Lung : The : Weig	rs ng/kg body weight ive al gland ignificance of these fi e, female onths ng/kg body weight ive s, Mammary gland, Ut ignificance of these fi nt of evidence does n	terus (including cervix)
Speci Applic Expos LOAE Resul Targe Rema Speci Applic Expos LOAE Resul Targe Resul	es cation Route sure time :L t Organs urks es cation Route sure time :L t t Organs irks	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 N : 500 : nega : Lung : The	rs ng/kg body weight ive al gland ignificance of these fi e, female onths ng/kg body weight ive s, Mammary gland, Ut ignificance of these fi nt of evidence does n	ndings for humans is not certain. terus (including cervix) ndings for humans is not certain.
Speci Applic Expose LOAE Resul Targe Rema Speci Applic Expose LOAE Resul Targe Rema Carcir ment	es cation Route sure time :L t t Organs irks es cation Route sure time :L t t Organs irks hogenicity - Assess-	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 N : 500 : nega : Lun : The : Weig cino	rs ng/kg body weight ive al gland ignificance of these fi e, female onths ng/kg body weight ive s, Mammary gland, Ut ignificance of these fi nt of evidence does men	ndings for humans is not certain. terus (including cervix) ndings for humans is not certain.
Speci Applic Expose LOAE Resul Targe Rema Speci Applic Expose LOAE Resul Targe Rema Carcir ment Repro	es cation Route sure time L t Organs irks es cation Route sure time L t Organs irks hogenicity - Assess- oductive toxicity assified based on ava	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 N : 500 : nega : Lun : The : Weig cino	rs ng/kg body weight ive al gland ignificance of these fi e, female onths ng/kg body weight ive s, Mammary gland, Ut ignificance of these fi nt of evidence does men	ndings for humans is not certain. terus (including cervix) ndings for humans is not certain.
Speci Applic Expose LOAE Resul Targe Rema Speci Applic Expose LOAE Resul Targe Rema Carcir ment Repro Not cl	es cation Route sure time EL t t Organs urks es cation Route sure time EL t t Organs urks hogenicity - Assess- oductive toxicity assified based on ava ponents:	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 N : 500 : nega : Lun : The : Weig cino	rs ng/kg body weight ive al gland ignificance of these fi e, female onths ng/kg body weight ive s, Mammary gland, Ut ignificance of these fi nt of evidence does men	ndings for humans is not certain. terus (including cervix) ndings for humans is not certain.
Speci Applic Expose LOAE Resul Targe Rema Speci Applic Expose LOAE Resul Targe Rema Carcir ment Repro Not cl	es cation Route sure time L t Organs irks es cation Route sure time L t Organs irks hogenicity - Assess- oductive toxicity assified based on ava	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 N : 500 : nega : Lun : The : Weig cino	rs ng/kg body weight ive al gland ignificance of these fi e, female onths ng/kg body weight ive s, Mammary gland, Ut ignificance of these fi nt of evidence does men	ndings for humans is not certain. terus (including cervix) ndings for humans is not certain.
Speci Applic Expose LOAE Resul Targe Rema Speci Applic Expose LOAE Resul Targe Rema Carcir ment Repro Not cl Comp	es cation Route sure time EL t t Organs irks es cation Route sure time EL t t Organs irks hogenicity - Assess- oductive toxicity assified based on ava ponents:	: Rat : Oral : 2 Ye : 300 : nega : Adre : The : Mou : Oral : 18 N : 500 : nega : Lung : The : Weig cino	rs ng/kg body weight ive al gland ignificance of these fi e, female onths ng/kg body weight ive s, Mammary gland, Ut ignificance of these fi nt of evidence does men	ndings for humans is not certain. terus (including cervix) ndings for humans is not certain. ot support classification as a car-



ersion 14	Revision Date: 30.09.2023		0S Number: 825-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014
				e: Oral 7,5 mg/kg body weight esting did not show any effects on fertility.
Effect ment	s on foetal develop-	:	Result: Embryoto	
			Result: Embryoto	
• •		2-hyd		morpholino-1,2,5-thiadiazole monomaleat
Effect	s on fertility	:	Species: Rat Application Rout Fertility: NOAEL	ity/early embryonic development e: Oral Mating/Fertility: 150 mg/kg body weight Development: NOAEL F1: 150 mg/kg body
Effect ment	s on foetal develop-	:	Species: Rabbit Developmental T	yo-foetal development oxicity: LOAEL F1: 50 mg/kg body weight idence of adverse effects on development, experiments.
Repro sessn	oductive toxicity - As- nent	:	Some evidence of animal experime	of adverse effects on development, based o nts.
	- single exposure assified based on avai	lable	information.	
STOT	- repeated exposure			
	es damage to organs (Lungs) through prolon			n, Central nervous system, Gastrointestinal ure.
<u>Produ</u>				
Targe	et Organs	:	Cardio-vascular tinal tract, Lungs	system, Central nervous system, Gastrointe
Asses	ssment	:	, 0	to organs through prolonged or repeated
<u>Comp</u>	oonents:			
Dorzo	plamide:			
Targe	t Organs	:	Central nervous Bladder	system, Gastrointestinal tract, Bone, Blood,



sion 4	Revision Date: 30.09.2023	SDS Numbe 28825-0002				
Assessment		•	: May cause damage to organs through prolonged or repeated exposure.			
(S)-3-	[3-(tert-butylamino)	2-hydroxyprop	oxy]-4-morpholino-1,2,5-thiadiazole monomalea			
	t Organs		ardio-vascular system			
Asses	sment	: Causes of exposure	damage to organs through prolonged or repeated e.			
Repea	ated dose toxicity					
<u>Comp</u>	oonents:					
Dorzo	olamide:					
Specie	es	: Rat				
NOAE	EL	: 0,05 mg/	kg			
Applic	ation Route	: Oral				
Targe	t Organs	: Bladder,	Kidney			
Specie	es	: Dog				
NOAE		: 0,05 mg/	kg			
LOAE		: 2 mg/kg				
	ation Route	: Oral				
	sure time	: 1 yr				
Targe	t Organs	: Gastroin	testinal tract, Bone, Blood			
Specie		: Monkey				
NOAE		: 0,05 mg/	kg			
	sure time	: 1 yr				
Targe	t Organs	: Gastroin	testinal tract, Bone, Blood			
(S)-3-	[3-(tert-butylamino)	2-hydroxyprop	oxy]-4-morpholino-1,2,5-thiadiazole monomalea			
Specie	es	: Rat				
NOAE		: 25 mg/kg	1			
	ation Route	: Oral				
	sure time	: 67 Week	S			
Specie	es	: Dog				
NOAE	EL	: 10 mg/kg]			
Applic	ation Route	: Oral				
	sure time	: 54 Week	S			
Targe	t Organs	: Kidney				
Aspir	ation toxicity					
•	assified based on ava	ailable informatio	n.			
Exper	rience with human e	xposure				
<u>Produ</u>	<u>ıct:</u>					
	ontact	burning o Dizzines	ns: The most common side effects are:, bitter taste, or stinging of the eye, Blurred vision, Abdominal pair s, digestive disorder, eye pain, Headache, hyperten usea, upper respiratory tract infection			



Version 3.14	Revision Date: 30.09.2023	SDS Number: 28825-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014
Com	oonents:		
Dorzo	olamide:		
Eye c	contact		ourning or stinging of the eye, Blurred vision, tear- , bitter taste, Nausea, dry mouth, Headache
(S)-3-	-[3-(tert-butylamino)	-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Eye c	contact	eyes, Heada	ourning or stinging of the eye, dryness of the che, Nausea, Dizziness, dry mouth, changes in ss, Allergic reactions
Inges	tion	: Symptoms: I trointestinal	Headache, Fatigue, Respiratory disorders, Gas- discomfort, Allergic reactions, Rash, hair loss, al status, Dizziness, changes in libido

SECTION 12: Ecological information

12.1 Toxicity

Components:

Dorzolamide:		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 1.000 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 699 mg/l Exposure time: 48 h
Toxicity to microorganisms	:	EC50 (Natural microorganism): > 800 mg/l Exposure time: 3 h
		Test Type: Respiration inhibition
		Method: OECD Test Guideline 209
(S)-3-[3-(tert-butylamino)-2-h	nyd	roxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

ate: (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-i orpno 0-1,2,:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 411 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 161 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to microorganisms	:	EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition
		EC50 (Photobacterium phosphoreum): > 1.800 mg/l

12.2 Persistence and degradability

Components:

Dorzolamide:

Biodegradability	:	Result: not rapidly degradable
		Biodegradation: 5 %
		Exposure time: 28 d



Version 3.14	Revision Date: 30.09.2023		DS Number: 825-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014
			Method: OECD T	est Guideline 314
(S)-3-	[3-(tert-butylamino)-2-	-hyd	roxypropoxy]-4-n	norpholino-1,2,5-thiadiazole monomaleate:
	gradability	:	Result: Not readil Biodegradation: Exposure time: 30	y biodegradable. 0 %
Stabili	ty in water	:	Hydrolysis: 0 %(6 Method: FDA 3.0	
12.3 Bioac	cumulative potential			
<u>Comp</u>	onents:			
Dorzo	lamide:			
	on coefficient: n- ol/water	:	log Pow: 0,292	
.,		hyd		orpholino-1,2,5-thiadiazole monomaleate:
	on coefficient: n- ol/water	:	log Pow: 1,48	
12.4 Mobil No da	ity in soil ta available			
12.5 Resul	lts of PBT and vPvB a	sse	ssment	
Produ	ict:			
Asses	sment	:	to be either persis	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of
12.6 Other	adverse effects			
Produ	<u>ict:</u>			
Endoc tial	rine disrupting poten-	:	ered to have ende REACH Article 57	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.
SECTION	13: Disposal consi	dera	ations	
13.1 Waste	e treatment methods			
Produ		:	According to the lare not product sp Waste codes sho discussion with th	ordance with local regulations. European Waste Catalogue, Waste Codes pecific, but application specific. uld be assigned by the user, preferably in he waste disposal authorities.
Conta	minated packaging	:		f waste into sewer. should be taken to an approved waste han- cling or disposal.
			14 / 17	



Version 3.14	Revision Date: 30.09.2023	SDS Number: 28825-00022	Date of last issue: 04.04.2023 Date of first issue: 06.11.2014
		If not other	wise specified: Dispose of as unused product.
SECTIO	N 14: Transport info	ormation	
14.1 UN r	number		
ADN		: Not regulat	ed as a dangerous good
ADR		: Not regulat	ed as a dangerous good
RID		: Not regulat	ed as a dangerous good
IMDO	3	: Not regulat	ed as a dangerous good
ΙΑΤΑ	L .	: Not regulat	ed as a dangerous good
14.2 UN p	proper shipping name	9	
ADN		: Not regulat	ed as a dangerous good
ADR		-	ed as a dangerous good
RID		: Not regulat	ed as a dangerous good
IMDO	3	: Not regulat	ed as a dangerous good
ΙΑΤΑ	L .	: Not regulat	ed as a dangerous good
14.3 Tran	sport hazard class(e	s)	
ADN		: Not regulat	ed as a dangerous good
ADR		-	ed as a dangerous good
RID		: Not regulat	ed as a dangerous good
IMDO	3	: Not regulat	ed as a dangerous good
ΙΑΤΑ	L .	: Not regulat	ed as a dangerous good
14.4 Pack	king group		
ADN		: Not regulat	ed as a dangerous good
ADR		: Not regulat	ed as a dangerous good
RID		: Not regulat	ed as a dangerous good
IMDO	3	: Not regulat	ed as a dangerous good
ΙΑΤΑ	(Cargo)	: Not regulat	ed as a dangerous good
ΙΑΤΑ	(Passenger)	: Not regulat	ed as a dangerous good
14.5 Envi	ronmental hazards		
Not r	egulated as a dangero	ous good	
-	cial precautions for u applicable	ser	
14 7 Tran	sport in bulk accord	ing to Anney II of	Marpol and the IBC Code

14.7 Transport in bulk according to Annex II of Marpol and the IBC CodeRemarks: Not applicable for product as supplied.



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.14	30.09.2023	28825-00022	Date of first issue: 06.11.2014

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H302	:	Harmful if swallowed.
H361d	:	Suspected of damaging the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure.
H373	:	May cause damage to organs through prolonged or repeated exposure.
Full text of other abbreviations		
Acute Tox.	:	Acute toxicity

Acute Tox. :	Acute toxicity
Repr. :	Reproductive toxicity
STOT RE :	Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road: AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - Interna-tional Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - Interna-



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.14	30.09.2023	28825-00022	Date of first issue: 06.11.2014

tional Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

H372

Classification of the mixture:

STOT RE 1

Classification procedure:

Based on product data or assessment

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN